Results 181 to 190 of about 2,485,203 (260)

A case series of necrotizing periodontal diseases in hospitalized patients: What hasn't been said yet?

Clinical Advances in Periodontics, EarlyView.
Abstract Background Necrotizing periodontal diseases (NPDs) are uncommon and severe inflammatory conditions characterized by tissue necrosis, painful ulceration, and rapid clinical progression, frequently associated with systemic immunosuppression. Limited data exist regarding their clinical presentation and management in hospital settings.
Osmaria Letthycia Carvalho Leal, Fernanda Bortolotto, Mariana Cristina Manoel, Gabriela Silveira de Araújo, Ana Carolina Fragoso Motta, Leandro Dorigan de Macedo, Lara Maria Alencar Ramos Innocentini, Joab Cabral Ramos, Isabel Schausltz Pereira Faustino   +8 more
wiley   +1 more source

8 Implication of the HIV-1 pol gene intragenic enhancer in myeloid-specific viral gene expression

Journal of Virus Eradication, 2017
R. Verdikt, L. Colin, C. Vanhulle, B. Van Driessche, A. Kula, V. Monceaux, N. Delacourt, A. David, A. Saez-Cirion, C. Van Lint   +9 more
doaj   +1 more source

The Case of a 40-Year-Old Man With New-Onset Status Epilepticus in the Setting of HIV Infection. [PDF]

Ann Clin Transl Neurol
Akhil V, Nandhagopal R.
europepmc   +1 more source

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

Clinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary, Robert Bies, Osei Boateng, Rachel Daley, Pierre Gashema, Mili Karina, Emily Njuguna, Sharon Nachman, Nathaniel Nkrumah, Carolyne Odula, Andrew Owen, Ethel D. Weld, Prajith Venkatasubramanian, Adeniyi Olagunju, on behalf of the Community of Practice for Long‐acting Therapeutics for Maternal and Paediatric Health, Rana Abutaima, Dorothy Akongo, Abdulnaser Alsharaa, Moherndran Archary, Shakir Atoyebi, Benoit Bestgen, Robert Bies, Osei Boateng, Andrew Butler, Edmund Capparelli, Rachel Daley, Layla Davies, Joelle Dountio, Henry Enzama, Pierre Gashema, Katila George, Dan Hawcutt, Rene Holm, Patrick Gad Iradukunda, Elodie Jambert, Mili Karina, Linda Lewis, Grace Miheso, Sebastien Morin, Andrew Morrison, Sharon Nachman, Shadia Nakalema, Emily Njunga, Nathaniel Nkrumah, Carolyne Odula‐Obonyo, Brenda Okware, Adeniyi Olagunju, Andrew Owen, Martina Penazzato, Natella Rakhmanina, Mphako Brighton Ratlabyana, Rachel Scott, Kimberly Struble, Andre‐Marie Tchouatieu, Catherine Unsworth, Prajith Venkatasubramanian, Catriona Waitt, Ethel Weld, Janine Winterbottom, Leena Zino   +59 more
wiley   +1 more source

Dynamics of virological suppression and systemic immune-inflammatory response following antiretroviral therapy in pediatric HIV infection. [PDF]

Front Cell Infect Microbiol
Uşaklıoğlu Erol M, Kaçmaz BB, Somer A, Hançerli Törün S.   +3 more
europepmc   +1 more source

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

Clinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian, Moherndran Archary, Daniel B. Hawcutt, Rachel Daley, Edmund Capparelli, Adeniyi Olagunju   +5 more
wiley   +1 more source

A Darwinian model for the evolution of drug resistance to long-acting PrEP during an early HIV infection. [PDF]

PLoS One
Gurski K, Kang Y, Ma Y.
europepmc   +1 more source

Empirical PK/PD Model for Differentiating Intrinsic Dosing Rules by Therapeutic Indication With Relevance for HIV‐1 Latency Reversal

Clinical Pharmacology &Therapeutics, EarlyView.
Romidepsin (RMD), an FDA‐approved histone deacetylase inhibitor for treating cancer, demonstrates potent latency‐reversing activity in vitro but has yielded suboptimal outcomes in kick‐and‐kill HIV‐cure trials when administered as a 5 mg/m2 infusion.
Lauren A. R. Tompkins, Amanda Poliseno, Airlie Ward, Edward P. Browne, Cassandra Gilbert, Craig Sykes, Angela D. M. Kashuba, Mackenzie L. Cottrell   +7 more
wiley   +1 more source

Testicular toll with viral intrusion: Molecular insights into the impact of chronic HIV infection on male fertility. [PDF]

Clin Transl Med
Hediyal TA, Stone EM, Shukri O, Schaal VL, Foroughi-Nezhad A, Devanaboyina M, Crenshaw JS, Elrefaie A, Kolli S, Davis CN, Pradhan D, Yelamanchili SV, Pendyala G.   +12 more
europepmc   +1 more source

Trust, but Verify: Translating Dosing Evidence to Understudied Populations in Low‐ and Middle‐Income Countries

Clinical Pharmacology &Therapeutics, EarlyView.
Drug dosing recommendations derived from healthy volunteers and selected preregistration populations may not translate reliably to physiologically distinct or understudied groups, particularly in low‐ and middle‐income countries. Using a metformin–dolutegravir drug interaction study and colistin pharmacokinetic study from South Africa, we illustrate ...
Roland van Rensburg, Veshni Pillay‐Fuentes Lorente, Eric Decloedt   +2 more
wiley   +1 more source